QR Code

Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses

In multiple models of oncolytic virotherapy, it is common to see an early anti-tumor response followed by recurrence. We have previously shown that frontline treatment with oncolytic VSV-IFN-β induces APOBEC proteins, promoting the selection of specific mutations that allow tumor escape. Of these mu...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Mason J. Webb, Timothy Kottke, Benjamin L. Kendall, Jack Swanson, Chisom Uzendu, Jason Tonne, Jill Thompson, Muriel Metko, Madelyn Moore, Mitesh Borad, Lewis Roberts, Rosa M. Diaz, Michael Olin, Antonella Borgatti, Richard Vile
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Elsevier 2023-06-01
Rangatū:Molecular Therapy: Oncolytics
Ngā marau:
oncolytic virotherapy
immunotherapy
CSDE1
vesicular stomatitis virus
VSV
melanoma
Urunga tuihono:http://www.sciencedirect.com/science/article/pii/S2372770523000396
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite